Local Triamcinolone Injection in Active Thyroid Orbitopathy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2011 by HaEmek Medical Center, Israel.
Recruitment status was  Not yet recruiting
Information provided by:
HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
First received: January 15, 2011
Last updated: January 19, 2011
Last verified: January 2011
Comparing the effectiveness of subconjunctival and peribulbar Triamcinolone injection to systemic Steroid therapy for patients with active thyroid orbitopathy.

Condition Intervention
Thyroid Disease
Drug: Triamcinolone

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Peribulbar and Subconjunctival Kenalog Injection for Thyroid Orbitopathy

Resource links provided by NLM:

Further study details as provided by HaEmek Medical Center, Israel:

Primary Outcome Measures:
  • Comparing the effectiveness of subconjunctival and peribulbar Triamcinolone injection to systemic Steroid therapy for patients with active thyroid orbitopathy . [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

    Every month, each participant will undergo several tests : blood sugar, full ocular examination, color test, visual field and ultrasound test for measuring the thickness of extraocular muscles.Clinical activity score for thyroid orbitopathy will be assesed too. The results of the clinical and ultrasonogrophic findings will determine the effectiveness of the treatment.

    A patient with deterioration of thyroid orbitopathy during the research, will be treated by systemic Steroids in addition to the local injections.

Secondary Outcome Measures:
  • To check if the level of TSH Receptor antibodies are affected by the local injection. [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]
    A blood test for TSH Receptor antibodies will be taken for every patient at the beginnig of the research and after 4 months.

Estimated Enrollment: 30
Study Start Date: February 2011
Estimated Study Completion Date: February 2013
Estimated Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Triamcinolone Drug: Triamcinolone
Subconjunctival and peribulbar, 40 mg/ml, 3 monthly injection
Other Name: kenalog

Detailed Description:

Local Steroid treatment may help in active thyroid orbitopathy. till today, systemic Steroids are the treatment for active thyroid orbitopathy which is associated with systemic adverse effects.

In this study the investigators want to compare the effectiveness of local Triamcinolone therapy for active thyroid orbitopathy.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age>18 years.
  • Active thyroid orbitopathy according to clinical activity score>=3.

Exclusion Criteria:

  • Intraorbital or active infections.
  • Tuberculosis.
  • Other orbital disease.
  • Pregnancy.
  • Compressive optic neuropathy.
  • Systemic steroid therapy within 6 months of study start.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01280214

Contact: Daniel Briscoe, MD 972-4-6494344 daniel_br@clalit.org.il

Sponsors and Collaborators
HaEmek Medical Center, Israel
Study Chair: Daniel Briscoe, MD haemek medical center
  More Information

Responsible Party: Dr Daniel Briscoe, Haemek Medical center
ClinicalTrials.gov Identifier: NCT01280214     History of Changes
Other Study ID Numbers: EMC119710ctil 
Study First Received: January 15, 2011
Last Updated: January 19, 2011
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Graves Ophthalmopathy
Thyroid Diseases
Autoimmune Diseases
Endocrine System Diseases
Eye Diseases
Eye Diseases, Hereditary
Graves Disease
Immune System Diseases
Orbital Diseases
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Anti-Inflammatory Agents
Enzyme Inhibitors
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 25, 2016